{"protocolSection":{"identificationModule":{"nctId":"NCT04559243","orgStudyIdInfo":{"id":"LAAC-01"},"organization":{"fullName":"Lifetech Scientific (Shenzhen) Co., Ltd.","class":"INDUSTRY"},"briefTitle":"Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events","officialTitle":"A Prospective, Multicenter Clinical Study of Percutaneous Left Atrial Appendage Closure as Secondary Prevention of Atrial Fibrillation-related Embolic Events in Patients With Atrial Fibrillation"},"statusModule":{"statusVerifiedDate":"2022-11","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-11-12","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-11","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-09-14","studyFirstSubmitQcDate":"2020-09-20","studyFirstPostDateStruct":{"date":"2020-09-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-12-15","lastUpdatePostDateStruct":{"date":"2022-12-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Lifetech Scientific (Shenzhen) Co., Ltd.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This clinical study is a prospective, multi-center, non-interventional study designed to investigate the safety and effectiveness of percutaneous LAA appendage closure by using LAmbre™ Left Atrial Appendage Occluder System. 579 patients with valvular AF complicated with previous AF-related embolic events (including ischemic stroke, TIA and systemic embolism) were enrolled at about 20 study sites nationwide. The baseline data, operation process and relevant follow-up information of subjects were recorded at 7 months after operation or before discharge and at 1, 3, 6, 12 and 24 months after operation.","detailedDescription":"Study Population Patients with non-valvular atrial fibrillation and previous AF-related embolic events Purpose To assess the feasibility and safety of percutaneous LAA closure as secondary prevention for patients with non-valvular atrial fibrillation (NVAF) and previous atrial fibrillation (AF) related embolic events (including ischemic stroke, transient ischemic attack (TIA), and systemic embolism)."},"conditionsModule":{"conditions":["Non-valvular Atrial Fibrillation","Embolic Stroke"],"keywords":["AF-related embolic events","non-valvular atrial fibrillation","Left Atrial Appendage Closure"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"ECOLOGIC_OR_COMMUNITY","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":579,"type":"ESTIMATED"}},"armsInterventionsModule":{"interventions":[{"type":"DIAGNOSTIC_TEST","name":"Transthoracic Echocardiography","description":"After the surgey, the tests data will be collected during 8 visits when the subjects go back to the hospital.","otherNames":["Transesophageal Echocardiography"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of new ischemic stroke, systemic embolism, and cardiac death 12 months after operation","description":"Ischemic stroke, systemic embolism, and cardiac death events","timeFrame":"12 months"},{"measure":"Incidence of major bleeding events (intracranial or gastrointestinal, or any bleeding requiring transfusion of ≥ 2 units of red blood cells) at 12 months after operation","description":"Bleeding events","timeFrame":"12 months"}],"secondaryOutcomes":[{"measure":"Surgical success rate","description":"Surgical success","timeFrame":"24 months"},{"measure":"Success rate of LAA closure at 3 months after operation","description":"Successful LAA closure was defined as a residual shunt ≤ 3 mm by TEE or ICE after implantation of the LAA occluder.","timeFrame":"3 months"},{"measure":"The composite endpoint of new ischemic stroke, systemic embolism and cardiac death at 7 months after operation or before discharge and at 1, 3, 6 and 24 months after operation","description":"Ischemic stroke, systemic embolism, and cardiac death events","timeFrame":"24 months"},{"measure":"(4)Perioperative (7 days after operation or before discharge) surgery-related complications","description":"7 days after operation or pre-discharge procedure-related complications include but are not limited to stroke (ischemic and hemorrhagic stroke), systemic embolism, allergic reaction, gas embolism, pericardial effusion/cardiac tamponade requiring intervention, occluder detachment, occluder thrombosis (DRT), minor bleeding events (including but not limited to puncture site hematoma, non-major bleeding events), infection, arrhythmia, damage to blood vessels or organs on the implantation path and adjacent organs","timeFrame":"7 days"},{"measure":"Procedure-related complications during follow-up","description":"Follow-up at 1, 3, 6, 12 and 24 months after operation for procedure-related complications, including all-cause death, stroke (ischemic and hemorrhagic stroke), cardiac perforation, pericardial effusion/cardiac tamponade requiring intervention, major bleeding events (intracranial or gastrointestinal, or any bleeding requiring transfusion of ≥ 2 units of red blood cells), occluder thrombosis (DRT), infection, systemic embolism, allergic reaction, arrhythmia, and other serious cardiovascular events requiring intervention or surgical treatment","timeFrame":"24 months"},{"measure":"Occluder defects during operation and in the 3rd month after operation","description":"Including but not limited: Occluder displacement, Occluder detachment, Occluder breakage, Occluder damage, etc","timeFrame":"3 months"},{"measure":"Incidence rate of severe adverse events within 24 months after operation","description":"including but not limited to all-cause death, events requiring hospitalization or prolongation of hospitalization, severe endocarditis requiring surgery, pericarditis, cardiac perforation, valvular injury, vascular or gas embolism events, occluder detachment/displacement, occluder fracture, occluder thrombosis (DRT), stroke events","timeFrame":"24 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥ 18 years, male or female;\n* Patients who are able to understand the purpose of the study, voluntarily participate in and sign the informed consent form (ICF), and are willing to complete the follow-up as required by the protocol;\n* Indications for left atrial appendage closure;\n* Patients with non-valvular AF complicated with previous AF related embolic event and meeting one of the following conditions;\n\n  1. HAS-BLED bleeding risk score ≥ 3 points;\n  2. Not suitable for long-term oral anticoagulant therapy;\n  3. Poor compliance with oral anticoagulants;\n  4. CHA2DS2-VASc score ≧ 2 points;\n\nExclusion Criteria:\n\n* Valvular AF (after moderate to severe mitral stenosis or mechanical valve replacement)\n* Initial AF, reversible AF with clear cause\n* Presence of adherent thrombus in the left atrium or left ventricular aneurysm thrombus\n* ST elevation myocardial infarction, ≤ 3 months\n* Grade-IV of Cardiac Function (NYHA)\n* Allergy or contraindication to metal nitinol, aspirin, clopidogrel, heparin, and other anticoagulants\n* Pregnant or with plan of pregnancy during the study\n* Participation in another drug or medical device clinical trial or study that has not been completed\n* Experience new stroke or TI within 30 days or major bleeding events within 14 days\n* Contraindication to LAA closure or deemed unsuitable for study participation by the investigator\n* Had a definite thromboembolic event","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients with non-valvular atrial fibrillation and previous AF-related embolic events","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Chenyang Jiang, Doctor","role":"CONTACT","phone":"8613857190051","email":"panshangming@lifetechmed.com"}],"overallOfficials":[{"name":"Chenyang Jiang, Doctor","affiliation":"Sir Run Run Shaw Hospital","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Jinhua Zhang, Doctor","affiliation":"Sir Run Run Shaw Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Qilu Hospital of Shandong University","status":"RECRUITING","city":"Jinan","state":"Shandong","zip":"250000","country":"China","contacts":[{"name":"Zhong Jingquan, Doctor","role":"CONTACT","phone":"18560086597","email":"18560086597@163.com"},{"name":"Zhong Jingquan, Doctor","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Shanghai Songjiang District Central Hospital","status":"RECRUITING","city":"Shanghai","state":"Shanghai","zip":"200000","country":"China","contacts":[{"name":"Zhao Wenbiao, Doctor","role":"CONTACT","phone":"18918288026"},{"name":"Zhao Wenbiao, Doctor","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Sichuan Mianyang 404 Hospital","status":"RECRUITING","city":"Mianyang","state":"Sichuan","zip":"621000","country":"China","contacts":[{"name":"Zhang Dayong, Doctor","role":"CONTACT","phone":"13890135264","email":"504082447@qq.com"},{"name":"Zhang Dayong, Doctor","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":31.46784,"lon":104.68168}},{"facility":"The first Affiliated Hospital of WMU","status":"RECRUITING","city":"Wenzhou","state":"Zhejiang","zip":"325600","country":"China","contacts":[{"name":"Huang Weijian, Doctor","role":"CONTACT","phone":"13806691086","email":"weijianhuang69@126.com"},{"name":"Huang Weijian, Doctor","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":27.99942,"lon":120.66682}},{"facility":"The Second Affiliated Hospital and Yuying Children's Hospital of WMU","status":"RECRUITING","city":"Wenzhou","state":"Zhejiang","zip":"325600","country":"China","contacts":[{"name":"Li Yuechun, Doctor","role":"CONTACT","phone":"13616776960","email":"liyuechun1980@sina.com"},{"name":"Li Yuechun, Doctor","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":27.99942,"lon":120.66682}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083262","term":"Embolic Stroke"},{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11997","name":"Neoplasm Metastasis","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M2403","name":"Embolic Stroke","asFound":"Embolic Stroke","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}